Research Paper Volume 16, Issue 9 pp 8070—8085

Figure 6. NAMPT/MitoROS regulated the SASP in HUVECs. (A) Histochemical detection of SA-β-gal-positive ECs in NAMPT knockdown HUVECs after knock-in of KLF4 or PDGFRA. Scale bar, 50 μm. Representative images (n=5) are shown. Blue, SA-β-gal-positive ECs. (B) Histochemical detection of SA-β-gal-positive ECs in NAMPT knock-in HUVECs after KLF4 or PDGFRA knockdown. Scale bar, 50 μm. Representative images (n=5) are shown. Blue, SA-β-gal-positive ECs. (C) Histochemical detection of SA-β-gal-positive ECs in MitoQ-treated HUVECs after KLF4 or PDGFRA knockdown. Scale bar, 50 μm. Representative images (n=5) are shown. Blue, SA-β-gal-positive ECs. (D) Western blotting analysis of p21 protein expression in NAMPT knock-in- or MitoQ-treated HUVECs (n=5). (E) Immunofluorescence detection of typical SAHF formation in cultured HUVECs after altering NAMPT expression or treatment with MitoQ (n=5). Scale bar, 20 μm. (F) qPCR analysis of cytokine mRNA levels in cultured HUVECs after altering NAMPT expression or treatment with MitoQ (n=5). *P < 0.05.